|
|
Exchange: |
OTC Bulletin Board |
Security
Type: |
N/A |
Shares
Out: |
26,519,000 |
Market
Cap: |
18.78(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0.55 - $1.72 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile VolitionRx is an epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop blood tests to help diagnose and monitor a range of life-altering diseases including certain cancers and diseases associated with NETosis such as sepsis and COVID-19. Co.'s tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. Co. is primarily focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
10,000 |
200,422 |
928,911 |
Total Buy Value |
$0 |
$8,300 |
$194,762 |
$1,588,869 |
Total People Bought |
0 |
1 |
11 |
12 |
Total Buy Transactions |
0 |
1 |
20 |
37 |
Total Shares Sold |
0 |
20,000 |
40,000 |
40,000 |
Total Sell Value |
$0 |
$18,000 |
$33,000 |
$33,000 |
Total People Sold |
0 |
1 |
1 |
1 |
Total Sell Transactions |
0 |
1 |
2 |
2 |
End Date |
2024-03-17 |
2023-12-15 |
2023-06-16 |
2022-06-16 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Innes Guy Archibald |
Director |
|
2017-04-18 |
4 |
OE |
$2.60 |
$194,535 |
D/D |
74,821 |
1,304,975 |
|
- |
|
Faulkes Martin Charles |
Director |
|
2017-04-03 |
4 |
OE |
$2.60 |
$150,888 |
D/D |
58,034 |
1,351,284 |
|
- |
|
Faulkes Martin Charles |
Director |
|
2016-11-25 |
4 |
D |
$4.44 |
$15,003 |
D/D |
(3,379) |
1,293,250 |
|
- |
|
Faulkes Martin Charles |
Director |
|
2016-11-25 |
4 |
OE |
$3.00 |
$15,000 |
D/D |
5,000 |
1,296,629 |
|
- |
|
Colman Alan |
Director |
|
2016-11-22 |
4 |
D |
$4.35 |
$15,003 |
D/D |
(3,449) |
156,250 |
|
- |
|
Colman Alan |
Director |
|
2016-11-22 |
4 |
OE |
$3.00 |
$15,000 |
D/D |
5,000 |
159,699 |
|
- |
|
Innes Guy Archibald |
Director |
|
2016-11-18 |
4 |
D |
$4.48 |
$15,004 |
D/D |
(3,349) |
1,230,154 |
|
- |
|
Innes Guy Archibald |
Director |
|
2016-11-18 |
4 |
OE |
$3.00 |
$15,000 |
D/D |
5,000 |
1,233,503 |
|
- |
|
Reynolds Cameron John |
President and CEO |
|
2016-11-18 |
4 |
D |
$4.48 |
$60,001 |
D/D |
(13,393) |
1,114,673 |
|
- |
|
Reynolds Cameron John |
President and CEO |
|
2016-11-18 |
4 |
OE |
$3.00 |
$60,000 |
D/D |
20,000 |
1,128,066 |
|
- |
|
Rootsaert Rodney Gerard |
Secretary |
|
2016-11-18 |
4 |
D |
$4.48 |
$30,003 |
D/D |
(6,697) |
4,828 |
|
- |
|
Rootsaert Rodney Gerard |
Secretary |
|
2016-11-18 |
4 |
OE |
$3.00 |
$30,000 |
D/D |
10,000 |
11,525 |
|
- |
|
Micallef Jacob Vincent |
Chief Scientific Officer |
|
2016-11-18 |
4 |
D |
$4.48 |
$60,001 |
I/I |
(13,393) |
38,113 |
|
- |
|
Micallef Jacob Vincent |
Chief Scientific Officer |
|
2016-11-18 |
4 |
OE |
$3.00 |
$60,000 |
I/I |
20,000 |
51,506 |
|
- |
|
Skaff Habib |
Director |
|
2016-11-11 |
4 |
D |
$4.30 |
$12,001 |
D/D |
(2,791) |
16,399 |
|
- |
|
Skaff Habib |
Director |
|
2016-11-11 |
4 |
OE |
$3.00 |
$12,000 |
D/D |
4,000 |
19,190 |
|
- |
|
Kratochvil David Matthew |
Chief Financial Officer |
|
2016-10-05 |
4 |
B |
$5.00 |
$50,000 |
D/D |
10,000 |
10,000 |
2.74 |
- |
|
Futcher Edward |
Director |
|
2016-06-23 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
356,000 |
|
- |
|
Futcher Edward |
Director |
|
2016-06-23 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
27,000 |
|
- |
|
Reynolds Cameron John |
President and CEO |
|
2016-06-16 |
4 |
D |
$3.39 |
$80,753 |
I/I |
(23,821) |
34,076 |
|
- |
|
Reynolds Cameron John |
President and CEO |
|
2016-06-16 |
4 |
OE |
$2.50 |
$80,750 |
I/I |
29,000 |
45,138 |
|
- |
|
Innes Guy Archibald |
Director |
|
2016-06-10 |
4 |
OE |
$0.50 |
$2,742 |
I/I |
5,484 |
47,940 |
|
- |
|
Faulkes Martin Charles |
Director |
|
2016-05-25 |
4 |
D |
$3.38 |
$15,000 |
D/D |
(4,438) |
1,291,629 |
|
- |
|
Faulkes Martin Charles |
Director |
|
2016-05-25 |
4 |
OE |
$3.00 |
$15,000 |
D/D |
5,000 |
1,296,067 |
|
- |
|
Skaff Habib |
Director |
|
2016-05-20 |
4 |
D |
$3.54 |
$12,001 |
D/D |
(3,390) |
15,190 |
|
- |
|
321 Records found
|
|
Page 11 of 13 |
|
|